Patents by Inventor Mary Ann Pohl

Mary Ann Pohl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-HPV ANTIBODIES AND USES THEREOF
    Publication number: 20240360202
    Abstract: The presently disclosed subject matter provides antibodies that mimic TCR recognition of HPV-derived epitopes presented by HLA class I molecules, antigen-recognizing receptors that target HPV-derived epitopes presented by HLA class I molecules, and methods of using such antibodies.
    Type: Application
    Filed: July 1, 2024
    Publication date: October 31, 2024
    Applicants: Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute for Cancer Research, Memorial Hospital for Cancer and Allied Diseases, Tri-Institutional Therapeutics Discovery Institute, Inc.
    Inventors: David A. Scheinberg, Tao Dao, Mary Ann Pohl, David Andrew, David Andrew
  • TCR MIMIC MONOCLONAL ANTIBODIES REACTIVE WITH THE PHOSPHO-NEOANTIGEN PIRS2/HLA-A*02:01 COMPLEX AND USES THEREOF
    Publication number: 20240239899
    Abstract: The present technology relates generally to compositions that specifically recognize and bind to a serine-phosphorylated IRS2 (pIRS2) peptide RVA[pS]PTSGVK (SEQ ID NO: 19) complexed with a major histocompatibility antigen (e.g., HLA-A*02). The compositions of the present technology are useful in methods for treating pIRS2-associated diseases (e.g., cancers) in a subject in need thereof.
    Type: Application
    Filed: May 19, 2022
    Publication date: July 18, 2024
    Inventors: Tao DAO, David A. SCHEINBERG, Paul BALDERES, Mary Ann POHL
  • ANTIGEN RECOGNIZING RECEPTORS TARGETING CD371 AND USES THEREOF
    Publication number: 20220213211
    Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target CD371 and cells comprising such CD371-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the CD371-targeted antigen-recognizing receptors for treatment.
    Type: Application
    Filed: March 11, 2022
    Publication date: July 7, 2022
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
    Inventors: Anthony Daniyan, Renier J. Brentjens, Ivo C. Lorenz, Mary Ann Pohl
  • ANTI-CD371 ANTIBODIES AND USES THEREOF
    Publication number: 20220195064
    Abstract: The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that bind to CD371 and methods of using such antibodies or antigen-binding fragments thereof same.
    Type: Application
    Filed: March 11, 2022
    Publication date: June 23, 2022
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
    Inventors: Anthony Daniyan, Renier J. Brentjens, Ivo C. Lorenz, Mary Ann Pohl
  • PRAME BINDING MOLECULES AND USES THEREOF
    Publication number: 20220153863
    Abstract: The present invention provides various PRAME binding molecules (including antibodies, antibody fragments, chimeric antigen receptors, and the like), compositions and cells (including T cells) comprising such PRAME binding molecules, and methods of using such PRAME binding molecules, compositions and cells, for example in the detection and/or monitoring of PRAME-positive tumors.
    Type: Application
    Filed: March 13, 2020
    Publication date: May 19, 2022
    Inventors: Hans David Staffan Ulmert, Richard John O'Reilly, Ivo Lorenz, Mary Ann Pohl, Namita Trikannad